nodes	percent_of_prediction	percent_of_DWPC	metapath
Oxaprozin—PTGS2—thyroid cancer	0.759	1	CbGaD
Oxaprozin—PTGS1—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.00584	0.142	CbGpPWpGaD
Oxaprozin—PTGS2—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.00464	0.113	CbGpPWpGaD
Oxaprozin—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.00439	0.107	CbGpPWpGaD
Oxaprozin—PTGS2—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.00349	0.0849	CbGpPWpGaD
Oxaprozin—PTGS1—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00239	0.0581	CbGpPWpGaD
Oxaprozin—PTGS2—Signaling mediated by p38-alpha and p38-beta—KRT19—thyroid cancer	0.00208	0.0506	CbGpPWpGaD
Oxaprozin—PTGS2—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00189	0.0462	CbGpPWpGaD
Oxaprozin—PTGS1—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00159	0.0386	CbGpPWpGaD
Oxaprozin—PTGS2—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00126	0.0307	CbGpPWpGaD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—RET—thyroid cancer	0.00123	0.03	CbGpPWpGaD
Oxaprozin—CYP2C9—Arachidonic acid metabolism—HPGD—thyroid cancer	0.000834	0.0203	CbGpPWpGaD
Oxaprozin—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—thyroid cancer	0.000788	0.0192	CbGpPWpGaD
Oxaprozin—Decreased appetite—Vandetanib—thyroid cancer	0.000769	0.00387	CcSEcCtD
Oxaprozin—Constipation—Vandetanib—thyroid cancer	0.000757	0.00381	CcSEcCtD
Oxaprozin—Arrhythmia—Sorafenib—thyroid cancer	0.00075	0.00377	CcSEcCtD
Oxaprozin—Alopecia—Sorafenib—thyroid cancer	0.000742	0.00373	CcSEcCtD
Oxaprozin—Gastrointestinal pain—Vandetanib—thyroid cancer	0.000724	0.00364	CcSEcCtD
Oxaprozin—Dysgeusia—Sorafenib—thyroid cancer	0.000716	0.0036	CcSEcCtD
Oxaprozin—Body temperature increased—Vandetanib—thyroid cancer	0.000699	0.00352	CcSEcCtD
Oxaprozin—Abdominal pain—Vandetanib—thyroid cancer	0.000699	0.00352	CcSEcCtD
Oxaprozin—Rectal haemorrhage—Epirubicin—thyroid cancer	0.000684	0.00344	CcSEcCtD
Oxaprozin—Anaemia—Sorafenib—thyroid cancer	0.000676	0.0034	CcSEcCtD
Oxaprozin—Glossitis—Epirubicin—thyroid cancer	0.000671	0.00337	CcSEcCtD
Oxaprozin—Oliguria—Epirubicin—thyroid cancer	0.000671	0.00337	CcSEcCtD
Oxaprozin—Angioedema—Sorafenib—thyroid cancer	0.000668	0.00336	CcSEcCtD
Oxaprozin—Syncope—Sorafenib—thyroid cancer	0.000656	0.0033	CcSEcCtD
Oxaprozin—Leukopenia—Sorafenib—thyroid cancer	0.000655	0.00329	CcSEcCtD
Oxaprozin—Ulcer—Epirubicin—thyroid cancer	0.000654	0.00329	CcSEcCtD
Oxaprozin—Loss of consciousness—Sorafenib—thyroid cancer	0.000643	0.00323	CcSEcCtD
Oxaprozin—Asthenia—Vandetanib—thyroid cancer	0.000635	0.00319	CcSEcCtD
Oxaprozin—Rectal haemorrhage—Doxorubicin—thyroid cancer	0.000633	0.00319	CcSEcCtD
Oxaprozin—Hypertension—Sorafenib—thyroid cancer	0.000631	0.00318	CcSEcCtD
Oxaprozin—Pruritus—Vandetanib—thyroid cancer	0.000626	0.00315	CcSEcCtD
Oxaprozin—Glossitis—Doxorubicin—thyroid cancer	0.000621	0.00312	CcSEcCtD
Oxaprozin—Oliguria—Doxorubicin—thyroid cancer	0.000621	0.00312	CcSEcCtD
Oxaprozin—PTGS1—Overview of nanoparticle effects—PTGS2—thyroid cancer	0.000617	0.015	CbGpPWpGaD
Oxaprozin—Dry mouth—Sorafenib—thyroid cancer	0.000609	0.00306	CcSEcCtD
Oxaprozin—Eructation—Epirubicin—thyroid cancer	0.000607	0.00305	CcSEcCtD
Oxaprozin—Diarrhoea—Vandetanib—thyroid cancer	0.000605	0.00304	CcSEcCtD
Oxaprozin—Ulcer—Doxorubicin—thyroid cancer	0.000605	0.00304	CcSEcCtD
Oxaprozin—Cystitis noninfective—Epirubicin—thyroid cancer	0.000604	0.00304	CcSEcCtD
Oxaprozin—Melaena—Epirubicin—thyroid cancer	0.000604	0.00304	CcSEcCtD
Oxaprozin—Cystitis—Epirubicin—thyroid cancer	0.000597	0.003	CcSEcCtD
Oxaprozin—Anaphylactic shock—Sorafenib—thyroid cancer	0.000597	0.003	CcSEcCtD
Oxaprozin—Infection—Sorafenib—thyroid cancer	0.000593	0.00298	CcSEcCtD
Oxaprozin—Shock—Sorafenib—thyroid cancer	0.000587	0.00295	CcSEcCtD
Oxaprozin—Dizziness—Vandetanib—thyroid cancer	0.000585	0.00294	CcSEcCtD
Oxaprozin—Thrombocytopenia—Sorafenib—thyroid cancer	0.000584	0.00294	CcSEcCtD
Oxaprozin—Aplastic anaemia—Epirubicin—thyroid cancer	0.00058	0.00292	CcSEcCtD
Oxaprozin—Anorexia—Sorafenib—thyroid cancer	0.000569	0.00286	CcSEcCtD
Oxaprozin—Oesophagitis—Epirubicin—thyroid cancer	0.000565	0.00284	CcSEcCtD
Oxaprozin—Coma—Epirubicin—thyroid cancer	0.000565	0.00284	CcSEcCtD
Oxaprozin—Vomiting—Vandetanib—thyroid cancer	0.000563	0.00283	CcSEcCtD
Oxaprozin—Eructation—Doxorubicin—thyroid cancer	0.000562	0.00283	CcSEcCtD
Oxaprozin—Ecchymosis—Epirubicin—thyroid cancer	0.000559	0.00281	CcSEcCtD
Oxaprozin—Bladder pain—Epirubicin—thyroid cancer	0.000559	0.00281	CcSEcCtD
Oxaprozin—Melaena—Doxorubicin—thyroid cancer	0.000559	0.00281	CcSEcCtD
Oxaprozin—Cystitis noninfective—Doxorubicin—thyroid cancer	0.000559	0.00281	CcSEcCtD
Oxaprozin—Rash—Vandetanib—thyroid cancer	0.000558	0.00281	CcSEcCtD
Oxaprozin—Dermatitis—Vandetanib—thyroid cancer	0.000557	0.0028	CcSEcCtD
Oxaprozin—Headache—Vandetanib—thyroid cancer	0.000554	0.00279	CcSEcCtD
Oxaprozin—Cystitis—Doxorubicin—thyroid cancer	0.000552	0.00278	CcSEcCtD
Oxaprozin—Aplastic anaemia—Doxorubicin—thyroid cancer	0.000537	0.0027	CcSEcCtD
Oxaprozin—Sepsis—Epirubicin—thyroid cancer	0.000537	0.0027	CcSEcCtD
Oxaprozin—Dyspnoea—Sorafenib—thyroid cancer	0.000532	0.00268	CcSEcCtD
Oxaprozin—Lymphadenopathy—Epirubicin—thyroid cancer	0.000526	0.00265	CcSEcCtD
Oxaprozin—Nausea—Vandetanib—thyroid cancer	0.000526	0.00264	CcSEcCtD
Oxaprozin—Dyspepsia—Sorafenib—thyroid cancer	0.000525	0.00264	CcSEcCtD
Oxaprozin—Oesophagitis—Doxorubicin—thyroid cancer	0.000523	0.00263	CcSEcCtD
Oxaprozin—Coma—Doxorubicin—thyroid cancer	0.000523	0.00263	CcSEcCtD
Oxaprozin—Decreased appetite—Sorafenib—thyroid cancer	0.000519	0.00261	CcSEcCtD
Oxaprozin—Ecchymosis—Doxorubicin—thyroid cancer	0.000517	0.0026	CcSEcCtD
Oxaprozin—Bladder pain—Doxorubicin—thyroid cancer	0.000517	0.0026	CcSEcCtD
Oxaprozin—Fenbufen—PTGS2—thyroid cancer	0.000516	0.49	CrCbGaD
Oxaprozin—PTGS1—Eicosanoid Synthesis—PTGS2—thyroid cancer	0.000512	0.0125	CbGpPWpGaD
Oxaprozin—Photosensitivity—Epirubicin—thyroid cancer	0.000511	0.00257	CcSEcCtD
Oxaprozin—Constipation—Sorafenib—thyroid cancer	0.00051	0.00257	CcSEcCtD
Oxaprozin—Vascular purpura—Epirubicin—thyroid cancer	0.000502	0.00252	CcSEcCtD
Oxaprozin—Hepatic failure—Epirubicin—thyroid cancer	0.000499	0.00251	CcSEcCtD
Oxaprozin—Sepsis—Doxorubicin—thyroid cancer	0.000496	0.0025	CcSEcCtD
Oxaprozin—Cardiac failure congestive—Epirubicin—thyroid cancer	0.000495	0.00249	CcSEcCtD
Oxaprozin—Gastrointestinal pain—Sorafenib—thyroid cancer	0.000488	0.00245	CcSEcCtD
Oxaprozin—Lymphadenopathy—Doxorubicin—thyroid cancer	0.000487	0.00245	CcSEcCtD
Oxaprozin—Renal failure acute—Epirubicin—thyroid cancer	0.000486	0.00244	CcSEcCtD
Oxaprozin—Dermatitis exfoliative—Epirubicin—thyroid cancer	0.000476	0.00239	CcSEcCtD
Oxaprozin—Urticaria—Sorafenib—thyroid cancer	0.000474	0.00238	CcSEcCtD
Oxaprozin—Photosensitivity—Doxorubicin—thyroid cancer	0.000473	0.00238	CcSEcCtD
Oxaprozin—Abdominal pain—Sorafenib—thyroid cancer	0.000472	0.00237	CcSEcCtD
Oxaprozin—Body temperature increased—Sorafenib—thyroid cancer	0.000472	0.00237	CcSEcCtD
Oxaprozin—Renal impairment—Epirubicin—thyroid cancer	0.000472	0.00237	CcSEcCtD
Oxaprozin—Purpura—Epirubicin—thyroid cancer	0.000466	0.00234	CcSEcCtD
Oxaprozin—Vascular purpura—Doxorubicin—thyroid cancer	0.000464	0.00233	CcSEcCtD
Oxaprozin—Anaphylactoid reaction—Epirubicin—thyroid cancer	0.000464	0.00233	CcSEcCtD
Oxaprozin—Hepatic failure—Doxorubicin—thyroid cancer	0.000462	0.00232	CcSEcCtD
Oxaprozin—Lethargy—Epirubicin—thyroid cancer	0.000458	0.0023	CcSEcCtD
Oxaprozin—Cardiac failure congestive—Doxorubicin—thyroid cancer	0.000458	0.0023	CcSEcCtD
Oxaprozin—Renal failure acute—Doxorubicin—thyroid cancer	0.00045	0.00226	CcSEcCtD
Oxaprozin—Gastrointestinal haemorrhage—Epirubicin—thyroid cancer	0.000449	0.00226	CcSEcCtD
Oxaprozin—Dermatitis exfoliative—Doxorubicin—thyroid cancer	0.00044	0.00221	CcSEcCtD
Oxaprozin—Renal impairment—Doxorubicin—thyroid cancer	0.000436	0.00219	CcSEcCtD
Oxaprozin—Purpura—Doxorubicin—thyroid cancer	0.000431	0.00217	CcSEcCtD
Oxaprozin—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.00043	0.0105	CbGpPWpGaD
Oxaprozin—Anaphylactoid reaction—Doxorubicin—thyroid cancer	0.000429	0.00216	CcSEcCtD
Oxaprozin—Asthenia—Sorafenib—thyroid cancer	0.000428	0.00215	CcSEcCtD
Oxaprozin—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.000428	0.0104	CbGpPWpGaD
Oxaprozin—Lethargy—Doxorubicin—thyroid cancer	0.000424	0.00213	CcSEcCtD
Oxaprozin—Pruritus—Sorafenib—thyroid cancer	0.000422	0.00212	CcSEcCtD
Oxaprozin—Gastrointestinal haemorrhage—Doxorubicin—thyroid cancer	0.000415	0.00209	CcSEcCtD
Oxaprozin—Abdominal pain upper—Epirubicin—thyroid cancer	0.00041	0.00206	CcSEcCtD
Oxaprozin—Diarrhoea—Sorafenib—thyroid cancer	0.000408	0.00205	CcSEcCtD
Oxaprozin—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.000404	0.00203	CcSEcCtD
Oxaprozin—PTGS1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000401	0.00978	CbGpPWpGaD
Oxaprozin—Gastritis—Epirubicin—thyroid cancer	0.000397	0.002	CcSEcCtD
Oxaprozin—Dizziness—Sorafenib—thyroid cancer	0.000395	0.00199	CcSEcCtD
Oxaprozin—Asthma—Epirubicin—thyroid cancer	0.000388	0.00195	CcSEcCtD
Oxaprozin—Eosinophilia—Epirubicin—thyroid cancer	0.000384	0.00193	CcSEcCtD
Oxaprozin—Pancreatitis—Epirubicin—thyroid cancer	0.00038	0.00191	CcSEcCtD
Oxaprozin—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	0.00038	0.00925	CbGpPWpGaD
Oxaprozin—Vomiting—Sorafenib—thyroid cancer	0.000379	0.00191	CcSEcCtD
Oxaprozin—Abdominal pain upper—Doxorubicin—thyroid cancer	0.000379	0.00191	CcSEcCtD
Oxaprozin—Rash—Sorafenib—thyroid cancer	0.000376	0.00189	CcSEcCtD
Oxaprozin—Dermatitis—Sorafenib—thyroid cancer	0.000376	0.00189	CcSEcCtD
Oxaprozin—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.000374	0.00188	CcSEcCtD
Oxaprozin—Headache—Sorafenib—thyroid cancer	0.000374	0.00188	CcSEcCtD
Oxaprozin—Pancytopenia—Epirubicin—thyroid cancer	0.000368	0.00185	CcSEcCtD
Oxaprozin—Gastritis—Doxorubicin—thyroid cancer	0.000368	0.00185	CcSEcCtD
Oxaprozin—Dysuria—Epirubicin—thyroid cancer	0.000363	0.00182	CcSEcCtD
Oxaprozin—PTGS2—Spinal Cord Injury—LGALS3—thyroid cancer	0.000361	0.00879	CbGpPWpGaD
Oxaprozin—Asthma—Doxorubicin—thyroid cancer	0.000359	0.00181	CcSEcCtD
Oxaprozin—Eosinophilia—Doxorubicin—thyroid cancer	0.000355	0.00179	CcSEcCtD
Oxaprozin—Nausea—Sorafenib—thyroid cancer	0.000355	0.00178	CcSEcCtD
Oxaprozin—Photosensitivity reaction—Epirubicin—thyroid cancer	0.000354	0.00178	CcSEcCtD
Oxaprozin—Pancreatitis—Doxorubicin—thyroid cancer	0.000352	0.00177	CcSEcCtD
Oxaprozin—Hyperglycaemia—Epirubicin—thyroid cancer	0.00035	0.00176	CcSEcCtD
Oxaprozin—Pneumonia—Epirubicin—thyroid cancer	0.000348	0.00175	CcSEcCtD
Oxaprozin—Drowsiness—Epirubicin—thyroid cancer	0.000346	0.00174	CcSEcCtD
Oxaprozin—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.000343	0.00172	CcSEcCtD
Oxaprozin—Pancytopenia—Doxorubicin—thyroid cancer	0.000341	0.00171	CcSEcCtD
Oxaprozin—Renal failure—Epirubicin—thyroid cancer	0.00034	0.00171	CcSEcCtD
Oxaprozin—Stomatitis—Epirubicin—thyroid cancer	0.000337	0.0017	CcSEcCtD
Oxaprozin—Jaundice—Epirubicin—thyroid cancer	0.000337	0.0017	CcSEcCtD
Oxaprozin—Conjunctivitis—Epirubicin—thyroid cancer	0.000336	0.00169	CcSEcCtD
Oxaprozin—Dysuria—Doxorubicin—thyroid cancer	0.000336	0.00169	CcSEcCtD
Oxaprozin—Haematuria—Epirubicin—thyroid cancer	0.00033	0.00166	CcSEcCtD
Oxaprozin—Photosensitivity reaction—Doxorubicin—thyroid cancer	0.000328	0.00165	CcSEcCtD
Oxaprozin—Sinusitis—Epirubicin—thyroid cancer	0.000324	0.00163	CcSEcCtD
Oxaprozin—Hyperglycaemia—Doxorubicin—thyroid cancer	0.000324	0.00163	CcSEcCtD
Oxaprozin—Agranulocytosis—Epirubicin—thyroid cancer	0.000323	0.00162	CcSEcCtD
Oxaprozin—Pneumonia—Doxorubicin—thyroid cancer	0.000322	0.00162	CcSEcCtD
Oxaprozin—Drowsiness—Doxorubicin—thyroid cancer	0.00032	0.00161	CcSEcCtD
Oxaprozin—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000317	0.0016	CcSEcCtD
Oxaprozin—Renal failure—Doxorubicin—thyroid cancer	0.000315	0.00158	CcSEcCtD
Oxaprozin—Haemoglobin—Epirubicin—thyroid cancer	0.000312	0.00157	CcSEcCtD
Oxaprozin—Jaundice—Doxorubicin—thyroid cancer	0.000312	0.00157	CcSEcCtD
Oxaprozin—Stomatitis—Doxorubicin—thyroid cancer	0.000312	0.00157	CcSEcCtD
Oxaprozin—Conjunctivitis—Doxorubicin—thyroid cancer	0.000311	0.00156	CcSEcCtD
Oxaprozin—Haemorrhage—Epirubicin—thyroid cancer	0.00031	0.00156	CcSEcCtD
Oxaprozin—Hepatitis—Epirubicin—thyroid cancer	0.00031	0.00156	CcSEcCtD
Oxaprozin—Haematuria—Doxorubicin—thyroid cancer	0.000305	0.00153	CcSEcCtD
Oxaprozin—Sinusitis—Doxorubicin—thyroid cancer	0.0003	0.00151	CcSEcCtD
Oxaprozin—Agranulocytosis—Doxorubicin—thyroid cancer	0.000299	0.0015	CcSEcCtD
Oxaprozin—Phenylbutazone—PTGS2—thyroid cancer	0.000297	0.281	CrCbGaD
Oxaprozin—Erythema multiforme—Epirubicin—thyroid cancer	0.000294	0.00148	CcSEcCtD
Oxaprozin—Tinnitus—Epirubicin—thyroid cancer	0.000289	0.00146	CcSEcCtD
Oxaprozin—Haemoglobin—Doxorubicin—thyroid cancer	0.000289	0.00145	CcSEcCtD
Oxaprozin—Hepatitis—Doxorubicin—thyroid cancer	0.000287	0.00144	CcSEcCtD
Oxaprozin—Haemorrhage—Doxorubicin—thyroid cancer	0.000287	0.00144	CcSEcCtD
Oxaprozin—PTGS2—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—PPARG—thyroid cancer	0.000287	0.007	CbGpPWpGaD
Oxaprozin—PTGS1—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000285	0.00693	CbGpPWpGaD
Oxaprozin—Arrhythmia—Epirubicin—thyroid cancer	0.000277	0.00139	CcSEcCtD
Oxaprozin—Alopecia—Epirubicin—thyroid cancer	0.000274	0.00138	CcSEcCtD
Oxaprozin—Erythema multiforme—Doxorubicin—thyroid cancer	0.000272	0.00137	CcSEcCtD
Oxaprozin—Tinnitus—Doxorubicin—thyroid cancer	0.000268	0.00135	CcSEcCtD
Oxaprozin—Flatulence—Epirubicin—thyroid cancer	0.000266	0.00134	CcSEcCtD
Oxaprozin—Tension—Epirubicin—thyroid cancer	0.000265	0.00133	CcSEcCtD
Oxaprozin—Dysgeusia—Epirubicin—thyroid cancer	0.000265	0.00133	CcSEcCtD
Oxaprozin—Nervousness—Epirubicin—thyroid cancer	0.000263	0.00132	CcSEcCtD
Oxaprozin—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.00026	0.00634	CbGpPWpGaD
Oxaprozin—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000259	0.00631	CbGpPWpGaD
Oxaprozin—Arrhythmia—Doxorubicin—thyroid cancer	0.000257	0.00129	CcSEcCtD
Oxaprozin—Vision blurred—Epirubicin—thyroid cancer	0.000255	0.00128	CcSEcCtD
Oxaprozin—Alopecia—Doxorubicin—thyroid cancer	0.000254	0.00128	CcSEcCtD
Oxaprozin—Ill-defined disorder—Epirubicin—thyroid cancer	0.000251	0.00126	CcSEcCtD
Oxaprozin—Anaemia—Epirubicin—thyroid cancer	0.00025	0.00126	CcSEcCtD
Oxaprozin—PTGS2—Spinal Cord Injury—CDK1—thyroid cancer	0.000246	0.00601	CbGpPWpGaD
Oxaprozin—Flatulence—Doxorubicin—thyroid cancer	0.000246	0.00124	CcSEcCtD
Oxaprozin—Tension—Doxorubicin—thyroid cancer	0.000245	0.00123	CcSEcCtD
Oxaprozin—Dysgeusia—Doxorubicin—thyroid cancer	0.000245	0.00123	CcSEcCtD
Oxaprozin—Malaise—Epirubicin—thyroid cancer	0.000244	0.00123	CcSEcCtD
Oxaprozin—Nervousness—Doxorubicin—thyroid cancer	0.000243	0.00122	CcSEcCtD
Oxaprozin—Vertigo—Epirubicin—thyroid cancer	0.000243	0.00122	CcSEcCtD
Oxaprozin—Syncope—Epirubicin—thyroid cancer	0.000242	0.00122	CcSEcCtD
Oxaprozin—Leukopenia—Epirubicin—thyroid cancer	0.000242	0.00122	CcSEcCtD
Oxaprozin—Flurbiprofen—PTGS2—thyroid cancer	0.000242	0.229	CrCbGaD
Oxaprozin—Palpitations—Epirubicin—thyroid cancer	0.000239	0.0012	CcSEcCtD
Oxaprozin—Loss of consciousness—Epirubicin—thyroid cancer	0.000238	0.00119	CcSEcCtD
Oxaprozin—Vision blurred—Doxorubicin—thyroid cancer	0.000236	0.00119	CcSEcCtD
Oxaprozin—Convulsion—Epirubicin—thyroid cancer	0.000234	0.00118	CcSEcCtD
Oxaprozin—Hypertension—Epirubicin—thyroid cancer	0.000233	0.00117	CcSEcCtD
Oxaprozin—Ill-defined disorder—Doxorubicin—thyroid cancer	0.000232	0.00117	CcSEcCtD
Oxaprozin—Anaemia—Doxorubicin—thyroid cancer	0.000231	0.00116	CcSEcCtD
Oxaprozin—Anxiety—Epirubicin—thyroid cancer	0.000229	0.00115	CcSEcCtD
Oxaprozin—Discomfort—Epirubicin—thyroid cancer	0.000227	0.00114	CcSEcCtD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000227	0.00552	CbGpPWpGaD
Oxaprozin—Malaise—Doxorubicin—thyroid cancer	0.000226	0.00113	CcSEcCtD
Oxaprozin—Dry mouth—Epirubicin—thyroid cancer	0.000225	0.00113	CcSEcCtD
Oxaprozin—Vertigo—Doxorubicin—thyroid cancer	0.000225	0.00113	CcSEcCtD
Oxaprozin—Syncope—Doxorubicin—thyroid cancer	0.000224	0.00113	CcSEcCtD
Oxaprozin—Leukopenia—Doxorubicin—thyroid cancer	0.000224	0.00113	CcSEcCtD
Oxaprozin—Confusional state—Epirubicin—thyroid cancer	0.000222	0.00112	CcSEcCtD
Oxaprozin—Palpitations—Doxorubicin—thyroid cancer	0.000221	0.00111	CcSEcCtD
Oxaprozin—Oedema—Epirubicin—thyroid cancer	0.000221	0.00111	CcSEcCtD
Oxaprozin—Anaphylactic shock—Epirubicin—thyroid cancer	0.000221	0.00111	CcSEcCtD
Oxaprozin—Loss of consciousness—Doxorubicin—thyroid cancer	0.00022	0.00111	CcSEcCtD
Oxaprozin—Infection—Epirubicin—thyroid cancer	0.000219	0.0011	CcSEcCtD
Oxaprozin—Shock—Epirubicin—thyroid cancer	0.000217	0.00109	CcSEcCtD
Oxaprozin—Convulsion—Doxorubicin—thyroid cancer	0.000217	0.00109	CcSEcCtD
Oxaprozin—Thrombocytopenia—Epirubicin—thyroid cancer	0.000216	0.00109	CcSEcCtD
Oxaprozin—Hypertension—Doxorubicin—thyroid cancer	0.000216	0.00109	CcSEcCtD
Oxaprozin—Tachycardia—Epirubicin—thyroid cancer	0.000215	0.00108	CcSEcCtD
Oxaprozin—Hyperhidrosis—Epirubicin—thyroid cancer	0.000213	0.00107	CcSEcCtD
Oxaprozin—PTGS1—Biological oxidations—RXRA—thyroid cancer	0.000213	0.0052	CbGpPWpGaD
Oxaprozin—Anxiety—Doxorubicin—thyroid cancer	0.000212	0.00107	CcSEcCtD
Oxaprozin—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000211	0.00514	CbGpPWpGaD
Oxaprozin—Discomfort—Doxorubicin—thyroid cancer	0.00021	0.00106	CcSEcCtD
Oxaprozin—Anorexia—Epirubicin—thyroid cancer	0.00021	0.00106	CcSEcCtD
Oxaprozin—Dry mouth—Doxorubicin—thyroid cancer	0.000208	0.00105	CcSEcCtD
Oxaprozin—Hypotension—Epirubicin—thyroid cancer	0.000206	0.00104	CcSEcCtD
Oxaprozin—Confusional state—Doxorubicin—thyroid cancer	0.000206	0.00103	CcSEcCtD
Oxaprozin—Anaphylactic shock—Doxorubicin—thyroid cancer	0.000204	0.00103	CcSEcCtD
Oxaprozin—Oedema—Doxorubicin—thyroid cancer	0.000204	0.00103	CcSEcCtD
Oxaprozin—Infection—Doxorubicin—thyroid cancer	0.000203	0.00102	CcSEcCtD
Oxaprozin—Shock—Doxorubicin—thyroid cancer	0.000201	0.00101	CcSEcCtD
Oxaprozin—Thrombocytopenia—Doxorubicin—thyroid cancer	0.0002	0.00101	CcSEcCtD
Oxaprozin—Insomnia—Epirubicin—thyroid cancer	0.0002	0.001	CcSEcCtD
Oxaprozin—Tachycardia—Doxorubicin—thyroid cancer	0.000199	0.001	CcSEcCtD
Oxaprozin—Paraesthesia—Epirubicin—thyroid cancer	0.000198	0.000996	CcSEcCtD
Oxaprozin—Hyperhidrosis—Doxorubicin—thyroid cancer	0.000197	0.000992	CcSEcCtD
Oxaprozin—Dyspnoea—Epirubicin—thyroid cancer	0.000197	0.000989	CcSEcCtD
Oxaprozin—Somnolence—Epirubicin—thyroid cancer	0.000196	0.000986	CcSEcCtD
Oxaprozin—Anorexia—Doxorubicin—thyroid cancer	0.000195	0.000978	CcSEcCtD
Oxaprozin—Dyspepsia—Epirubicin—thyroid cancer	0.000194	0.000977	CcSEcCtD
Oxaprozin—Decreased appetite—Epirubicin—thyroid cancer	0.000192	0.000964	CcSEcCtD
Oxaprozin—Hypotension—Doxorubicin—thyroid cancer	0.000191	0.000959	CcSEcCtD
Oxaprozin—Constipation—Epirubicin—thyroid cancer	0.000189	0.000949	CcSEcCtD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—NRAS—thyroid cancer	0.000188	0.00458	CbGpPWpGaD
Oxaprozin—Insomnia—Doxorubicin—thyroid cancer	0.000185	0.000928	CcSEcCtD
Oxaprozin—Paraesthesia—Doxorubicin—thyroid cancer	0.000183	0.000922	CcSEcCtD
Oxaprozin—Dyspnoea—Doxorubicin—thyroid cancer	0.000182	0.000915	CcSEcCtD
Oxaprozin—Feeling abnormal—Epirubicin—thyroid cancer	0.000182	0.000914	CcSEcCtD
Oxaprozin—Somnolence—Doxorubicin—thyroid cancer	0.000181	0.000913	CcSEcCtD
Oxaprozin—PTGS1—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000181	0.00441	CbGpPWpGaD
Oxaprozin—Gastrointestinal pain—Epirubicin—thyroid cancer	0.00018	0.000907	CcSEcCtD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00018	0.00438	CbGpPWpGaD
Oxaprozin—Dyspepsia—Doxorubicin—thyroid cancer	0.00018	0.000904	CcSEcCtD
Oxaprozin—PTGS2—Signaling mediated by p38-alpha and p38-beta—TP53—thyroid cancer	0.000179	0.00436	CbGpPWpGaD
Oxaprozin—Decreased appetite—Doxorubicin—thyroid cancer	0.000177	0.000892	CcSEcCtD
Oxaprozin—Urticaria—Epirubicin—thyroid cancer	0.000175	0.000881	CcSEcCtD
Oxaprozin—Constipation—Doxorubicin—thyroid cancer	0.000175	0.000878	CcSEcCtD
Oxaprozin—Abdominal pain—Epirubicin—thyroid cancer	0.000174	0.000877	CcSEcCtD
Oxaprozin—Body temperature increased—Epirubicin—thyroid cancer	0.000174	0.000877	CcSEcCtD
Oxaprozin—Feeling abnormal—Doxorubicin—thyroid cancer	0.000168	0.000846	CcSEcCtD
Oxaprozin—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000167	0.000839	CcSEcCtD
Oxaprozin—Urticaria—Doxorubicin—thyroid cancer	0.000162	0.000815	CcSEcCtD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—KRAS—thyroid cancer	0.000162	0.00394	CbGpPWpGaD
Oxaprozin—Abdominal pain—Doxorubicin—thyroid cancer	0.000161	0.000811	CcSEcCtD
Oxaprozin—Body temperature increased—Doxorubicin—thyroid cancer	0.000161	0.000811	CcSEcCtD
Oxaprozin—Asthenia—Epirubicin—thyroid cancer	0.000158	0.000796	CcSEcCtD
Oxaprozin—PTGS1—Metabolism—MINPP1—thyroid cancer	0.000157	0.00382	CbGpPWpGaD
Oxaprozin—Pruritus—Epirubicin—thyroid cancer	0.000156	0.000785	CcSEcCtD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—RXRA—thyroid cancer	0.000156	0.00379	CbGpPWpGaD
Oxaprozin—Diarrhoea—Epirubicin—thyroid cancer	0.000151	0.000759	CcSEcCtD
Oxaprozin—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.00015	0.00364	CbGpPWpGaD
Oxaprozin—Asthenia—Doxorubicin—thyroid cancer	0.000146	0.000736	CcSEcCtD
Oxaprozin—Dizziness—Epirubicin—thyroid cancer	0.000146	0.000734	CcSEcCtD
Oxaprozin—Pruritus—Doxorubicin—thyroid cancer	0.000144	0.000726	CcSEcCtD
Oxaprozin—Vomiting—Epirubicin—thyroid cancer	0.00014	0.000705	CcSEcCtD
Oxaprozin—Diarrhoea—Doxorubicin—thyroid cancer	0.00014	0.000702	CcSEcCtD
Oxaprozin—Rash—Epirubicin—thyroid cancer	0.000139	0.000699	CcSEcCtD
Oxaprozin—Dermatitis—Epirubicin—thyroid cancer	0.000139	0.000699	CcSEcCtD
Oxaprozin—Headache—Epirubicin—thyroid cancer	0.000138	0.000695	CcSEcCtD
Oxaprozin—PTGS2—Aryl Hydrocarbon Receptor—HRAS—thyroid cancer	0.000137	0.00335	CbGpPWpGaD
Oxaprozin—Dizziness—Doxorubicin—thyroid cancer	0.000135	0.000679	CcSEcCtD
Oxaprozin—PTGS2—C-MYB transcription factor network—CCND1—thyroid cancer	0.000135	0.00328	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—NDUFA13—thyroid cancer	0.000133	0.00325	CbGpPWpGaD
Oxaprozin—Nausea—Epirubicin—thyroid cancer	0.000131	0.000659	CcSEcCtD
Oxaprozin—Vomiting—Doxorubicin—thyroid cancer	0.00013	0.000653	CcSEcCtD
Oxaprozin—Rash—Doxorubicin—thyroid cancer	0.000129	0.000647	CcSEcCtD
Oxaprozin—Dermatitis—Doxorubicin—thyroid cancer	0.000129	0.000647	CcSEcCtD
Oxaprozin—Headache—Doxorubicin—thyroid cancer	0.000128	0.000643	CcSEcCtD
Oxaprozin—PTGS2—Disease—TRIM24—thyroid cancer	0.000126	0.00308	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—CHST14—thyroid cancer	0.000125	0.00305	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—MINPP1—thyroid cancer	0.000124	0.00303	CbGpPWpGaD
Oxaprozin—Nausea—Doxorubicin—thyroid cancer	0.000121	0.00061	CcSEcCtD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000119	0.0029	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—CHST14—thyroid cancer	0.000119	0.00289	CbGpPWpGaD
Oxaprozin—PTGS2—C-MYB transcription factor network—NRAS—thyroid cancer	0.000116	0.00283	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—TRIM33—thyroid cancer	0.000113	0.00274	CbGpPWpGaD
Oxaprozin—CYP2C9—Biological oxidations—RXRA—thyroid cancer	0.000112	0.00273	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—NDUFA13—thyroid cancer	0.000106	0.00258	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—CCND1—thyroid cancer	0.000103	0.0025	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—HPGD—thyroid cancer	0.000101	0.00246	CbGpPWpGaD
Oxaprozin—PTGS2—C-MYB transcription factor network—KRAS—thyroid cancer	9.99e-05	0.00243	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—CHST14—thyroid cancer	9.94e-05	0.00242	CbGpPWpGaD
Oxaprozin—PTGS2—C-MYB transcription factor network—HRAS—thyroid cancer	8.49e-05	0.00207	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—MINPP1—thyroid cancer	8.23e-05	0.00201	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	8.19e-05	0.00199	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—HPGD—thyroid cancer	8.01e-05	0.00195	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—TCF7L1—thyroid cancer	7.51e-05	0.00183	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—NDUFA13—thyroid cancer	7e-05	0.00171	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—CCND1—thyroid cancer	6.98e-05	0.0017	CbGpPWpGaD
Oxaprozin—PTGS2—Spinal Cord Injury—TP53—thyroid cancer	6.76e-05	0.00165	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—PTEN—thyroid cancer	6.74e-05	0.00164	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—CHST14—thyroid cancer	6.58e-05	0.0016	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	6.5e-05	0.00158	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—TPR—thyroid cancer	5.8e-05	0.00141	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—PRKAR1A—thyroid cancer	5.7e-05	0.00139	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—TPR—thyroid cancer	5.5e-05	0.00134	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—PRKAR1A—thyroid cancer	5.41e-05	0.00132	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—HPGD—thyroid cancer	5.31e-05	0.00129	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—KRAS—thyroid cancer	5.18e-05	0.00126	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	5.17e-05	0.00126	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—MEN1—thyroid cancer	5.17e-05	0.00126	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—TPR—thyroid cancer	4.6e-05	0.00112	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—TP53—thyroid cancer	4.6e-05	0.00112	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—PRKAR1A—thyroid cancer	4.53e-05	0.0011	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—SLC5A5—thyroid cancer	4.34e-05	0.00106	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	4.3e-05	0.00105	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—CALCA—thyroid cancer	4.11e-05	0.001	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	4.1e-05	0.001	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	4.07e-05	0.000991	CbGpPWpGaD
Oxaprozin—PTGS2—Integrated Pancreatic Cancer Pathway—AKT1—thyroid cancer	3.89e-05	0.000947	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—CDK1—thyroid cancer	3.72e-05	0.000907	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—RXRA—thyroid cancer	3.65e-05	0.000888	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	3.55e-05	0.000864	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—SLC5A5—thyroid cancer	3.44e-05	0.000839	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—TPR—thyroid cancer	3.05e-05	0.000743	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	3e-05	0.000731	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—NRG1—thyroid cancer	2.99e-05	0.000728	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—RXRA—thyroid cancer	2.89e-05	0.000705	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	2.82e-05	0.000686	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	2.72e-05	0.000662	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—TERT—thyroid cancer	2.68e-05	0.000654	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—HIF1A—thyroid cancer	2.57e-05	0.000625	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—PPARG—thyroid cancer	2.3e-05	0.000561	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—SLC5A5—thyroid cancer	2.28e-05	0.000556	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	2.14e-05	0.000521	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—BRAF—thyroid cancer	2.13e-05	0.000518	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—RXRA—thyroid cancer	1.92e-05	0.000467	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	1.86e-05	0.000454	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—PPARG—thyroid cancer	1.83e-05	0.000445	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—PTGS2—thyroid cancer	1.81e-05	0.000441	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—PTEN—thyroid cancer	1.58e-05	0.000385	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—PTEN—thyroid cancer	1.5e-05	0.000365	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—NRAS—thyroid cancer	1.34e-05	0.000325	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—PTEN—thyroid cancer	1.25e-05	0.000305	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—PPARG—thyroid cancer	1.21e-05	0.000295	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—KRAS—thyroid cancer	1.15e-05	0.00028	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—HRAS—thyroid cancer	9.77e-06	0.000238	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—PTGS2—thyroid cancer	9.52e-06	0.000232	CbGpPWpGaD
Oxaprozin—PTGS1—Metabolism—AKT1—thyroid cancer	9.1e-06	0.000222	CbGpPWpGaD
Oxaprozin—PTGS2—Disease—AKT1—thyroid cancer	8.63e-06	0.00021	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—PTEN—thyroid cancer	8.3e-06	0.000202	CbGpPWpGaD
Oxaprozin—PTGS2—Metabolism—AKT1—thyroid cancer	7.23e-06	0.000176	CbGpPWpGaD
Oxaprozin—CYP2C9—Metabolism—AKT1—thyroid cancer	4.78e-06	0.000117	CbGpPWpGaD
